|By Marketwired .||
|June 24, 2014 07:35 AM EDT||
CEDAR KNOLLS, NJ -- (Marketwired) -- 06/24/14 -- MYOS Corporation ("MYOS" or the "Company") (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that the Company has entered into a three-year Master Service Agreement ("MSA") with Rutgers, The State University of New Jersey, to engage Rutgers researchers in a program which will expand the MYOS' basic science platform for further development of Fortetropin, the first clinically proven natural myostatin inhibitor, and other proprietary MYOS product formulations.
The initial project with Rutgers will involve the development of cell-based assays for high throughput screening studies of next generation myostatin inhibitors such as peptides, proteins and small molecules. The program will be led by Joseph W. Freeman, Ph.D., Associate Professor, Department of Biomedical Engineering at Rutgers, and Principal Investigator along with his experienced team at the University's Musculoskeletal Tissue Regeneration Laboratory ("MoTR"). It is anticipated that the results of this program will allow MYOS to gain further insight into the mechanism of action of Fortetropin as it relates to myogenesis or the development of muscle tissue. MYOS expects the study to be completed mid-year 2015.
Dr. Freeman commented, "The Rutgers MoTR team is pleased to have the opportunity to collaborate with MYOS and learn more about Fortetropin and the characteristics of the Company's proprietary formulas and products which lower myostatin levels to affect an increase in muscle mass, stimulate muscle healing and offer a new therapeutic treatment option for sarcopenia, a condition of age-related loss of muscle mass."
"The program undertaken by Dr. Freeman is the first of many in which MYOS would like to engage with Rutgers over the next three years," commented Robert Ashton, M.D., Chief Medical Officer at MYOS. "We believe this opportunity to share our collective knowledge and to work closely with scientists who are experts in muscle health at the University's MoTR, will enable us to build out the MYOS research platform."
In addition to the newly announced agreement with Rutgers, MYOS is a corporate sponsor of Rutgers Athletics. The Company is proud to support the University's sporting events, including the Scarlet Knights Football program, as it joins the prestigious Big Ten Conference this year. The Rutgers Athletics partnership with MYOS was a facilitated through IMG College Inc., the collegiate sports marketing company that represents Rutgers.
About Rutgers, The State University of New Jersey
Established in 1766, Rutgers, The State University of New Jersey, is America's eighth oldest institution of higher learning and one of the nation's premier public research universities, serving more than 65,000 students on three campuses. Rutgers-New Brunswick is a member of the prestigious Association of American Universities and joins the Big Ten Conference in July. Rutgers ranks #1 among U.S. universities for chemistry R&D funding. The Office of Research and Economic Development provides a central point for industry to access Rutgers, including a new website, businessportal.rutgers.edu.
About MYOS Corporation
MYOS is a developmental stage bionutrition and biotherapeutics company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin (MYO-T12®), the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company," visit www.myoscorp.com.
The Company's first commercial product based on Fortetropin (MYO-T12®), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including http://mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin (MYO-T12®) and its effects on myostatin inhibition, including our research and development activities, product and customer demand, the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, the continued growth in market expansion and revenue including the expansion into the age management market, the successful entry into new markets including the age management market, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
MYOS Corporation Investor and Media Contact:
Investor Relations and Corporate Communications